Antibody-Drug Conjugates

DRUG3 trials

Sponsors

SOLTI Breast Cancer Research Group, Hellenic Cooperative Oncology Group, Jules Bordet Institute

Conditions

Advanced or Metastatic Solid TumourAlopeciaAntibody-Drug ConjugateBreast CancerMetastatic Breast CancerMetastatic Cancer

Phase 2

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

CompletedNCT02448420

SOLTI Breast Cancer Research GroupMetastatic Breast Cancer

Start: 2015-07-31End: 2023-11-30Updated: 2024-04-18

SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates

Not yet recruitingNCT07474558

Jules Bordet InstituteAdvanced or Metastatic Solid Tumour, Alopecia, Antibody-Drug Conjugate

Start: 2026-09-01End: 2031-09-01Target: 102Updated: 2026-08-19

Unknown Phase

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

CompletedNCT06504719

Hellenic Cooperative Oncology GroupBreast Cancer, Metastatic Cancer

Start: 2023-01-01End: 2024-09-01Updated: 2025-09-15

Related Papers

Data from Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial

2026-02-17

Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial.

2025-12-03

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.

2025-09-01

Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.

Journal of Clinical Oncology2024-05-298 citations

Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer

Clinical Cancer Research2023-06-2612 citations

Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study

Cancer Research2022-02-15

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.

Journal of Clinical Oncology2018-05-206 citations